retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished 🤔 Adults with type 2

8 GSH is the brains primary tool for neutralizing that internal pollution, alongside external stressors like environmental toxins and pollutants that reach the brain and add to its overall oxidative load

When it comes to taking GLP-1 medications for weight loss, side effects matterespecially when youre committing to a long-term plan

However, clinical trials such as STEP-4 demonstrate that weight regain typically occurs after discontinuation of therapy

Retatrutide is not available on the NHS as it has not received MHRA marketing authorisation

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of alzheimers disease

No medication replaces lifestyle